Now located in CA, Admunex is a âspin offâ company from the Higuchi Biosciences Center at the University of Kansas that is developing novel platform technologies to treat autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The companyâs primary technology involves a unique process of targeting and destroying the T-cells that cause autoimmune diseases. Admunex was founded to commercialize new medicines for the treatment of autoimmune diseases. Admunex's products are derived from patented inventions discovered in Professor Teruna Siahaan's research laboratory in the Pharmaceutical Chemistry Department at the University of Kansas (KU). Basic research to understand the cellular communication processes conducted in Professor Siahaan's research group lead to the discoveries and patented inventions. As a result of this new understanding of the cellular communication processes, Admunex scientists are able to exploit nature's cell biology to deliver existing and new therapeutic agents to the diseased cell. Rheumatoid arthritis (RA) and multiple sclerosis (MS) are the initial clinical targets for Admunex's cell-specific targeted drug delivery technolo
